Matches in SemOpenAlex for { <https://semopenalex.org/work/W594981419> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W594981419 endingPage "1757" @default.
- W594981419 startingPage "1757" @default.
- W594981419 abstract "1757 Objectives To report our initial experience using tositumomab and 131I-tositumomab (BEXXAR®,GlaxoSmithKline) for treatment of relapsed/refractory Hodgkin lymphoma (HL) in an ongoing phase I/II clinical trial. Methods After meeting eligibility criteria and providing informed written consent, patients (pts) were enrolled into separate dose-escalation studies for those with and without prior stem cell transplant, starting at 55 and 75 cGy total body radiation doses (TBD), respectively. Dosimetry imaging studies were performed after administration of 450 mg tositumomab and 5 mCi 131I-tositumomab. A single patient-specific therapeutic dosage of 450 mg tositumomab and 131I-tositumomab was then given. TBD was escalated/deescalated based on dose-limiting toxicity using a continual reassessment method (CRM). Results 10 pts (7 classical (c), 3 lymphocyte-predominant (LP) HL) have been enrolled. In the post-transplant group, 3 received a 55 cGy TBD of 131I-tositumomab and 1 received 79 cGy. 6 pts without prior transplant (n=3 with LPHL) received 75 or 87 (n=3, each) cGy TBD of 131I-tositumomab. The agent was well-tolerated in all cohorts, with no adverse events during infusion of the agent or grade 3/4 nonhematologic toxicity. The expected hematologic adverse events were common and transient, including grade 3/4 thrombocytopenia (n=2), neutropenia (n=2), lymphopenia (n=5), and grade 4 anemia (n=1). 2 pts with LPHL had a complete response 12 weeks post-131I-tositumomab, while 8 progressed (7 cHL, 1 LPHL). Conclusions Tositumomab and 131I-tositumomab can be safely administered to pts with relapsed/refractory HL. Major toxicities are hematologic. The CRM was successful for determining TBD for subsequent cohorts. Transplant recipients have tolerated higher doses than those previously reported in NHL. Complete responses in LPHL suggests some therapeutic effect of this agent against HL, particularly in this sub-type. Dose-escalation is ongoing. Research Support Research support is provided by GlaxoSmithKlin" @default.
- W594981419 created "2016-06-24" @default.
- W594981419 creator A5024722162 @default.
- W594981419 creator A5058888805 @default.
- W594981419 creator A5061859839 @default.
- W594981419 creator A5068593672 @default.
- W594981419 creator A5076437171 @default.
- W594981419 creator A5084381349 @default.
- W594981419 date "2011-05-01" @default.
- W594981419 modified "2023-09-27" @default.
- W594981419 title "Initial experience with tositumomab and iodine I 131 tositumomab for treatment of relapsed/refractory Hodgkin lymphoma" @default.
- W594981419 hasPublicationYear "2011" @default.
- W594981419 type Work @default.
- W594981419 sameAs 594981419 @default.
- W594981419 citedByCount "0" @default.
- W594981419 crossrefType "journal-article" @default.
- W594981419 hasAuthorship W594981419A5024722162 @default.
- W594981419 hasAuthorship W594981419A5058888805 @default.
- W594981419 hasAuthorship W594981419A5061859839 @default.
- W594981419 hasAuthorship W594981419A5068593672 @default.
- W594981419 hasAuthorship W594981419A5076437171 @default.
- W594981419 hasAuthorship W594981419A5084381349 @default.
- W594981419 hasConcept C121332964 @default.
- W594981419 hasConcept C126322002 @default.
- W594981419 hasConcept C142424586 @default.
- W594981419 hasConcept C143998085 @default.
- W594981419 hasConcept C197934379 @default.
- W594981419 hasConcept C2777063308 @default.
- W594981419 hasConcept C2778248108 @default.
- W594981419 hasConcept C29730261 @default.
- W594981419 hasConcept C2989005 @default.
- W594981419 hasConcept C71924100 @default.
- W594981419 hasConcept C87355193 @default.
- W594981419 hasConcept C90924648 @default.
- W594981419 hasConceptScore W594981419C121332964 @default.
- W594981419 hasConceptScore W594981419C126322002 @default.
- W594981419 hasConceptScore W594981419C142424586 @default.
- W594981419 hasConceptScore W594981419C143998085 @default.
- W594981419 hasConceptScore W594981419C197934379 @default.
- W594981419 hasConceptScore W594981419C2777063308 @default.
- W594981419 hasConceptScore W594981419C2778248108 @default.
- W594981419 hasConceptScore W594981419C29730261 @default.
- W594981419 hasConceptScore W594981419C2989005 @default.
- W594981419 hasConceptScore W594981419C71924100 @default.
- W594981419 hasConceptScore W594981419C87355193 @default.
- W594981419 hasConceptScore W594981419C90924648 @default.
- W594981419 hasLocation W5949814191 @default.
- W594981419 hasOpenAccess W594981419 @default.
- W594981419 hasPrimaryLocation W5949814191 @default.
- W594981419 hasRelatedWork W1850839548 @default.
- W594981419 hasRelatedWork W1967417752 @default.
- W594981419 hasRelatedWork W2024291442 @default.
- W594981419 hasRelatedWork W2063773276 @default.
- W594981419 hasRelatedWork W2145903752 @default.
- W594981419 hasRelatedWork W2165299754 @default.
- W594981419 hasRelatedWork W2278498280 @default.
- W594981419 hasRelatedWork W2342332142 @default.
- W594981419 hasRelatedWork W2469072249 @default.
- W594981419 hasRelatedWork W2541172026 @default.
- W594981419 hasRelatedWork W2563272068 @default.
- W594981419 hasRelatedWork W2580184094 @default.
- W594981419 hasRelatedWork W2583616819 @default.
- W594981419 hasRelatedWork W2590898097 @default.
- W594981419 hasRelatedWork W2601343457 @default.
- W594981419 hasRelatedWork W2604669391 @default.
- W594981419 hasRelatedWork W2778722372 @default.
- W594981419 hasRelatedWork W2946187815 @default.
- W594981419 hasRelatedWork W3186359575 @default.
- W594981419 hasRelatedWork W3191391573 @default.
- W594981419 hasVolume "52" @default.
- W594981419 isParatext "false" @default.
- W594981419 isRetracted "false" @default.
- W594981419 magId "594981419" @default.
- W594981419 workType "article" @default.